RxDoctor Payments Data

Robert Pick, DO

Cardiovascular Disease · Redding, CANPI 1982670592

Payments from drug & device makers

$12,616in general payments, 2019–2025

Across 364 payments — averaging $34.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$6K
  • Novartis$2K
  • Boston Scientific$1K
  • Abbott$1K
  • Abiomed$490
  • Amgen$280
  • plus $1K from 20 others

What the payments were for

  • Travel & lodging$2,62926%
  • Food & beverage$7,62274%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,616 in reported general payments places this provider in the 75th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$321,984
Medicare patients
688
Services billed
3,939

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban170$231,623
XareltoRivaroxaban127$160,319
Repatha SureclickEvolocumab36$52,409
Flecainide Acetate236$20,135
Ezetimibe217$8,889
BrilintaTicagrelor12$5,112
Rosuvastatin Calcium268$4,729
Amiodarone Hcl165$3,801
Metoprolol Succinate170$2,966
ClopidogrelClopidogrel Bisulfate186$2,151
Potassium Chloride74$2,143
Atorvastatin Calcium239$2,061
Albuterol Sulfate HfaAlbuterol Sulfate21$1,835
FenofibrateFenofibrate Nanocrystallized45$1,743
Losartan Potassium88$1,435

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$114$231,623170 claims
Johnson & JohnsonXarelto$22$160,319127 claims
AstraZenecaBrilinta$152$5,11212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Redding

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →